Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.

Bartlett, Nancy L

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. [electronic resource] - Journal of hematology & oncology Mar 2014 - 24 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

1756-8722

10.1186/1756-8722-7-24 doi


Adolescent
Adult
Aged
Brentuximab Vedotin
Female
Hodgkin Disease--drug therapy
Humans
Immunoconjugates--administration & dosage
Ki-1 Antigen--metabolism
Lymphoma, Large-Cell, Anaplastic--drug therapy
Male
Middle Aged
Molecular Targeted Therapy
Recurrence
Retreatment
Young Adult